Methods for treating inflammatory and autoimmune diseases
First Claim
1. A method for treating an inflammatory condition comprising administering to a subject with an inflammatory condition an amount effective to treat the inflammatory condition of a compound selected from the group consisting of narcistatin, pancratistatin, pancratastatin-7′
- phosphate and pancratastatin-3′
,4′
cyclic phosphate, or pharmaceutically acceptable salts thereof.
0 Assignments
0 Petitions
Accused Products
Abstract
The present invention provides methods for treating inflammatory conditions, rheumatoid diseases, autoimmune conditions, and conditions associated with bone loss, comprising administering to a subject with an inflammatory condition an amount effective to treat the condition of a compound selected from the group consisting of narcistatin, pancratistatin, pancratastatin-7′ phosphate and pancratastatin-3′,4′ cyclic phosphate, or pharmaceutically acceptable salts thereof.
-
Citations
15 Claims
-
1. A method for treating an inflammatory condition comprising administering to a subject with an inflammatory condition an amount effective to treat the inflammatory condition of a compound selected from the group consisting of narcistatin, pancratistatin, pancratastatin-7′
- phosphate and pancratastatin-3′
,4′
cyclic phosphate, or pharmaceutically acceptable salts thereof. - View Dependent Claims (2)
- phosphate and pancratastatin-3′
-
3. A method for treating arthritis, comprising administering to a subject with arthritis an amount effective to treat arthritis of a compound selected from the group consisting of narcistatin, pancratistatin, pancratastatin-7′
- phosphate and pancratastatin-3′
,4′
cyclic phosphate, or pharmaceutically acceptable salts thereof. - View Dependent Claims (4, 5)
- phosphate and pancratastatin-3′
-
6. A method for one or more of reducing bone loss in a subject, treating a rheumatoid disease, and/or treating an autoimmune disorder, comprising administering to a subject at risk of bone loss, suffering from a rheumatoid disease, and/or suffering from an autoimmune disorder an amount effective to reduce bone loss, treat a rheumatoid disease, and/or treat an autoimmune disorder of a compound selected from the group consisting of narcistatin, pancratistatin, pancratastatin-7′
- phosphate and pancratastatin-3′
,4′
cyclic phosphate, or pharmaceutically acceptable salts thereof. - View Dependent Claims (7)
- phosphate and pancratastatin-3′
-
8. A method for treating one or more disorders selected from the group consisting of osteoporosis, osteoarthritis, Paget'"'"'s disease, humoral hypercalcemia of malignancy, hypercalcemia from tumors metastatic to bone, and periodontal disease, comprising administering to a subject with one or more of the disorders an amount effective to treat the one or more disorders of a compound selected from the group consisting of sodium narcistatin, pancratistatin, pancratastatin-7′
- phosphate and pancratastatin-3′
,4′
cyclic phosphate, or pharmaceutically acceptable salts thereof. - View Dependent Claims (9, 10, 11, 12, 13, 14)
- phosphate and pancratastatin-3′
-
15. A method for reducing cellular production of one or more of vascular endothelial growth factor, nitric oxide, IL-1, MCP, and/or TNFα
- in a subject in need thereof comprising administering to the subject an amount effective to reduce cellular production or one or more of vascular endothelial growth factor, nitric oxide, IL-1, MCP, and/or TNFα
of a compound selected from the group consisting of narcistatin, pancratistatin, pancratastatin-7′
phosphate and pancratastatin-3′
,4′
cyclic phosphate, or pharmaceutically acceptable salts thereof.
- in a subject in need thereof comprising administering to the subject an amount effective to reduce cellular production or one or more of vascular endothelial growth factor, nitric oxide, IL-1, MCP, and/or TNFα
Specification